Compare OLMA & OSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLMA | OSS |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 229.6M |
| IPO Year | 2020 | 2017 |
| Metric | OLMA | OSS |
|---|---|---|
| Price | $13.61 | $16.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $44.89 | $10.00 |
| AVG Volume (30 Days) | 820.9K | ★ 2.2M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.00 | ★ 133.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $37,027,382.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | N/A | $20.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 34.46 |
| 52 Week Low | $3.89 | $2.37 |
| 52 Week High | $36.26 | $17.25 |
| Indicator | OLMA | OSS |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 74.98 |
| Support Level | $13.11 | $5.18 |
| Resistance Level | $17.23 | N/A |
| Average True Range (ATR) | 0.80 | 1.61 |
| MACD | -0.08 | 0.57 |
| Stochastic Oscillator | 19.67 | 91.45 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.